A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

Summary

This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's disease (AD). This study aims to determine whether administering ONO-2020, an epigenetic regulator, may improve cognitive functions like memory and cognition in individuals with Alzheimer's disease dementia.

Timeline

Start

2025-04-24

Primary completion

2026-07

Completion

2026-08

Drugs

Indications